The short version of chronic hepatitis B fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Einsteinium is a synthetic, silvery, radioactive metal. In the periodic table, it is located to the right of the actinide californium, to the left of the actinide fermium and below the lanthanide holmium with which it shares many similarities in physical and chemical properties. Its density of 8.84 g/cm3 is lower than that of californium (15.1 g/cm3) and is nearly the same as that of holmium (8.79 g/cm3), despite einsteinium being much heavier per atom than holmium. Einsteinium's melting point (860 °C) is also relatively low—below californium (900 °C), fermium (1,527 °C) and holmium (1,461 °C). Einsteinium is a soft metal, with a bulk modulus of only 15 GPa, one of the lowest among non-alkali metals. Unlike the lighter actinides californium, berkelium, curium and americium, which crystallize in a double hexagonal structure at ambient conditions; einsteinium is believed to have a face-centered cubic (fcc) symmetry with the space group Fm3m and the lattice constant a = 575 pm. However, there is a report of room-temperature hexagonal einsteinium metal with a = 398 pm and c = 650 pm, which converted to the fcc phase upon heating to 300 °C. The self-damage induced by the radioactivity of einsteinium is so strong that it rapidly destroys the crystal lattice, and the energy release during this process, 1000 watts per gram of 253Es, induces a visible glow. These processes may contribute to the relatively low density and melting point of einsteinium.
== Function == Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. The encoded enzyme is regulated by steroid hormones. In tissue culture, the enzyme has been found to generate amyloidogenic fragments from the amyloid precursor protein, suggesting a potential for involvement in Alzheimer's disease. Multiple alternatively spliced transcript variants that encode different isoforms have been identified for this gene.
=== Role of Elon Musk === On January 30, 2025, Elon Musk demanded that Jason Gray, acting administrator of USAID at that time, shut off email and cellphone access for USAID workers around the world, including in conflict zones. Gray refused, saying that doing so would put their lives at risk. By the next day, Gray was removed from his post. On February 3, 2025, Elon Musk, who has been carrying out parts of Trump's cost-cutting agenda, announced that he and Trump were in the process of shutting down USAID, claiming it to be a "criminal organization" and that it was "beyond repair". USAID's Inspector General had previously launched a probe into Starlink, which is operated by Musk; this led to concerns that Musk's role in the agency's downsizing constituted a conflict of interest.
== Medical uses == Probenecid is primarily used to treat gout and hyperuricemia. Probenecid is sometimes used to increase the concentration of some antibiotics and to protect the kidneys when given with cidofovir. Specifically, a small amount of evidence supports the use of intravenous cefazolin once rather than three times a day when it is combined with probenecid. It has also found use as a masking agent, potentially helping athletes using performance-enhancing substances to avoid detection by drug tests.
Sources: en.wikipedia.org
The problem of the diesels causing a vacuum in the submarine when the head valve is submerged still exists in later model diesel submarines but is mitigated by high-vacuum cut-off sensors that shut down the engines when the vacuum in the ship reaches a pre-set point. Modern snorkel induction masts have a fail-safe design using compressed air, controlled by a simple electrical circuit, to hold the "head valve" open against the pull of a powerful spring. Seawater washing over the mast shorts out exposed electrodes on top, breaking the control, and shutting the "head valve" while it is submerged. US submarines did not adopt the use of snorkels until after WWII.
Some of the heavier elements in the periodic table may be revealed to have yet-undiscovered isotopes with longer lifetimes than those listed here. About 338 nuclides are found naturally on Earth. These comprise not only the 286 primordials, but also include about 52 shorter-lived isotopes that either are daughters of primordial isotopes (such as radium from uranium) or are made by energetic natural processes, such as carbon-14 made from atmospheric nitrogen by bombardment from cosmic rays.
==== Intracrine actions of PTHrP in cardiac cells ==== PTHrP exists in multiple isoforms, with some retained intracellularly rather than secreted. In cardiac myocytes and vascular smooth muscle cells, intracrine PTHrP is known to localize within the nucleus, where it regulates gene transcription, modulates cell proliferation, and affects intracellular calcium handling. One of the hallmark intracrine functions of PTHrP is its ability to influence angiogenesis. Studies have shown that nuclear PTHrP interacts with ribosomal DNA to upregulate genes involved in endothelial cell proliferation and vascular development. This action mirrors other intracrine factors, such as VEGF, which also regulate angiogenesis through nuclear localization.
=== Post-peptide modifications === The modification required to biosynthesize mature chloroeremomycin include: oxidative cross-linking of aromatic rings, hydroxylation and chlorination of the two Tyr residues, methylation of Leu, and glycosylation at aa4 and aa6. The oxidative crosslinks are catalyzed by enzymes OxyA-C. The glycosylations are catalyzed by enzymes GtfA-C (coded by Orf11-13 respectively). The chlorinations are performed by enzymes encoded by Orf10 and 18.
== External links == "Galanin Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2007-04-24. Galanin+Receptors at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.